



<b>Title</b>	A Three-Dimensional Cell Culture Platform for Long Time-Scale Observations of Bio-Nano Interactions
<b>Authors(s)</b>	Muraca, Francesco, Alahmari, Amirah, Giannone, Valeria A., Adumeau, Laurent, Yan, Yan, McCafferty, Mura M., Dawson, Kenneth A.
<b>Publication date</b>	2019-11-04
<b>Publication information</b>	Muraca, Francesco, Amirah Alahmari, Valeria A. Giannone, Laurent Adumeau, Yan Yan, Mura M. McCafferty, and Kenneth A. Dawson. "A Three-Dimensional Cell Culture Platform for Long Time-Scale Observations of Bio-Nano Interactions" 13, no. 11 (November 4, 2019).
<b>Publisher</b>	ACS
<b>Item record/more information</b>	<a href="http://hdl.handle.net/10197/12162">http://hdl.handle.net/10197/12162</a>
<b>Publisher's statement</b>	This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Nano, copyright © 2019 American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see <a href="http://pubs.acs.org/doi/abs/10.1021/acsnano.9b07453">http://pubs.acs.org/doi/abs/10.1021/acsnano.9b07453</a> .
<b>Publisher's version (DOI)</b>	10.1021/acsnano.9b07453

Downloaded 2023-10-06T13:54:56Z

The UCD community has made this article openly available. Please share how this access benefits you. Your story matters! (@ucd\_oa)



© Some rights reserved. For more information

1 **A three-dimensional cell culture platform for long time-scale observations of bio-nano**  
2 **interactions**

3 Francesco Muraca<sup>a</sup>, Amirah Alahmari<sup>a</sup>, Valeria A. Giannone<sup>a,b</sup>, Laurent Adumeau<sup>a</sup>, Yan  
4 Yan<sup>a,b</sup>, Mura M. McCafferty<sup>a\*</sup>, Kenneth A. Dawson<sup>a\*</sup>

5 a: Centre for BioNano Interactions, University College Dublin, Belfield, Dublin 4; b: School  
6 of Biomolecular and Biomedical Science, University College Dublin, Belfield, Dublin 4.

7 \* kenneth.a.dawson@cbni.ucd.ie, mura.mccafferty@cbni.ucd.ie: Correspondence should be  
8 addressed to these authors.

9

10 **SUMMARY**

11 We know surprisingly little about the long-term outcomes for nanomaterials interacting with  
12 organisms. To date, most of what we know is derived from *in vivo* studies that limit the range  
13 of materials studied, and the scope of advanced molecular biology tools applied. Long-term *in*  
14 *vitro* nanoparticle studies are hampered by a lack of suitable models, as standard cell culture  
15 techniques present several drawbacks, while technical limitations render current 3D cellular  
16 spheroid models less suited. Now, by controlling the kinetic processes of cell assembly and  
17 division in a non-Newtonian culture medium, we engineer reproducible cell clusters of  
18 controlled size and phenotype, leading to a convenient and flexible long-term 3D culture that  
19 allows nanoparticle studies over many weeks in an *in vitro* setting. We present applications of  
20 this model for the assessment of intracellular polymeric and silica nanoparticle persistence, and  
21 found that hydrocarbon based polymeric nanoparticles undergo no apparent degradation over  
22 long time periods with no obvious biological impact, while amorphous silica nanoparticles  
23 degrade at different rates over several weeks, depending on their synthesis method.

24 Keywords: 3D cell culture, cell cycle, quiescence, bio-nano interactions, nanoparticle  
25 persistence, nanoparticle degradation, silica nanoparticles

27 Nanostructures can gain access to biological (intracellular and other) compartments where they  
28 may accumulate and slowly degrade, producing various by-products.<sup>1-4</sup> This differs from the  
29 more familiar scenarios of small molecules having short *in situ* cellular half-lives, or  
30 macroscopic material implants exposed to extracellular degradation, so it is unclear what can  
31 be learned about the fate of particles by analogy to those situations.

32 Broadly speaking, nanoparticle populations present diverse biomolecular surfaces leading to  
33 ‘scattergun’ interactions with various cells, tissues and organs (including the liver).<sup>5-12</sup> There  
34 they will be incorporated and processed within endogenous intra- and trans-cellular trafficking  
35 pathways,<sup>13-15</sup> however, instead of being cleared rapidly, they may be retained for extended  
36 periods of weeks, months, or longer.<sup>16-19</sup> This could lead to persistent signalling dysregulation  
37 or other adverse biological processes, and the slow degradation of the particle to secondary  
38 (and other downstream) metabolites.<sup>20-24</sup> Given this diversity of interaction modalities, in early  
39 explorations it was surprising for some that few detrimental biological effects were observed  
40 for ‘passive’ materials, not otherwise chemically toxic. Still, it must be emphasised that much  
41 of what we currently know comes from short-term *in vitro* cell-level studies extending over  
42 hours,<sup>21,25-29</sup> with limited information on the consequences of longer-term intracellular  
43 nanoparticle localisation. This is primarily due to a lack of suitable *in vitro* models to address  
44 this issue, as commonly used cell culture systems fail to capture the complex *in vivo*  
45 environment, and are unsuitable for long-term nanoparticle studies due to rapid dilution of the  
46 intracellular nanoparticle load by cell division.<sup>30,31</sup> Thus, with the exception of a few studies  
47 that apply cell spheroids,<sup>32-36</sup> the little information available on long-term particle  
48 accumulation, degradation and cellular responses is largely observational and limited in scope,  
49 being derived from specialised *in vivo* studies.<sup>19,23,37-40</sup>

50 Rather topical examples where simplified models could shed some highly desirable light on  
51 their long-term impacts include polymeric and silica nanoparticles. Polymeric nanoparticles  
52 are either manufactured, or result from degradation of bulk polymers in the environment, and  
53 silica nanoparticles are widely used in industrial processes. Currently, the systematic study of  
54 these issues (without the use of animals), is essentially blocked.

55 Here we describe a highly reproducible, long-term three-dimensional (3D) culture model of  
56 small cellular assemblies that possess the architecture and some *in vivo* phenotypical features  
57 that are particularly suitable for studying long-term nanoparticle exposure. They may be  
58 created using immortalized cell lines, without the deficits suffered by dividing cells. As these  
59 cell clusters assemble, they re-form inter-cellular junctions, and restore functions known to  
60 predominate in the native tissue. Moreover, the cells transition to a quiescent state, while  
61 remaining metabolically active, thereby avoiding the confounding effects of cell division. The  
62 architecture of these assemblies is well defined, and the arrangement of cells is such that most  
63 are accessible to the cluster surface, ensuring viability over many weeks and months. These  
64 cell clusters possess ideal characteristics for studying the long-term effects of nanoparticle  
65 exposure *in vitro*, and are applied here for the assessment of polymeric and silica nanoparticles  
66 over several weeks.

67

## 68 **Results**

69 *Long-term cell cluster architecture for nanoparticle exposure:* We grow controlled cell clusters  
70 by suspension of dividing cells in a non-Newtonian polymeric additive (hereafter referred to  
71 as suspension media) that acts as a low viscosity liquid at shorter length and motional time-  
72 scales, while damping motion at longer length and time scales. This allows for diffusion of  
73 nutrients and nanoparticles, while whole-cell motion is slow and multi-cell motion is  
74 essentially quenched. While attempts to improve control of cell cultures using the viscoelastic

75 properties of media have been discussed previously,<sup>41</sup> our exploration suggests this may be an  
76 important dimension in the creation of organoid-like structures in future. There are numerous  
77 approaches to achieving control over culture media viscosity at the different length scales (tens  
78 of nanometres to micron). Soft-gelling polymer complexes have the convenience that they are  
79 readily optimised by dilution, small changes of ionic strength or other simple experimental  
80 control parameters. Examples we have explored include an enzyme modified galactomannan  
81 (Guar gum) and xanthan blend additive.<sup>42</sup> There are many ways of achieving similar relevant  
82 viscoelastic responses, so for simplicity our results are based on a standardised and widely  
83 available formulation.

84 By tuning the viscoelastic properties of the suspension media, we can control the reproducible  
85 formation, and structural and functional evolution of small cell clusters. Besides the  
86 fundamental issue of cell growth and assembly kinetics (about which we still have much to  
87 learn), there are also other practical optimisations, such as the avoidance of cell dropping or  
88 attachment to the bottom of the plates by applying an agar coating before cell seeding in the  
89 suspension media (Figure 1a). A549 human lung epithelial cells have been used for the work  
90 presented here, and we also report the possibility to reproduce these characteristics with other  
91 cell lines (Supplementary Figure S1).

92

93 *Cluster growth kinetic stages:* The basic kinetic processes of cell cluster formation are deduced  
94 from different regimes of time-lapse microscopy captured over 5 days (Supplementary Videos  
95 1-7), with more detailed imaging and analysis used to follow the outcome in a quantitative  
96 manner. Early on, single ‘itinerant’ cells within the medium can move relatively short distances  
97 and divide; therefore, during the first several days, cell-cell associations primarily arise from  
98 engagement (collision) of nearby cells, and cell division. During this ‘core formation’ stage  
99 some cells engage briefly before continuing to move while others attach, leading to small core

100 clusters of two or three cells, after which, adjustments of cluster shape take place. After twenty-  
101 four hours there is progressive crossover to the second ‘cluster-maturation’ kinetic stage in  
102 which the (near-stable and increasingly immobile) ‘core’ clusters grow, partly via collision  
103 with itinerant cells and proximate small clusters, and partly by division of cells within the  
104 cluster (Supplementary Figures S2, S3). We also observe other rarer processes; for example, a  
105 cell (or two) that lies between two neighboring clusters can form a bridge between them to  
106 promote their merger. ‘Cluster stabilisation’ commences around day five, wherein most of the  
107 itinerant cells are exhausted, rapid cluster growth ends, and established clusters are essentially  
108 immobile (Figure 1b).

109 *Cluster size and shape evolution:* The distribution of the major (long) axis length of the  
110 growing and maturing clusters exhibits a tail and is therefore not strictly Gaussian (Figure 1c,  
111 Supplementary Figure S4 and Supplementary Table S1). While the origin of this small  
112 proportion of larger cluster size is not yet fully understood (it could be due to some cells  
113 reaching the agar-coated surface and forming slightly larger structures), if we extract a median  
114 or mean size from the distributions over time, the most rapid cluster size increase indeed  
115 accompanies the cluster growth stage, and changes slow dramatically after the first five days  
116 (Figure 1d). At the cluster stabilisation stage, the minor axis begins to be approximately  
117 described as a bilayer of cells. The fact that clusters are restricted in size (typically less than  
118 100  $\mu\text{m}$ ; Figure 1c-e and Supplementary Figure S4) and oblate in shape (Figure 1f and  
119 Supplementary Figure S5) means that most cells have access to nutrients, gas supply and waste  
120 clearance,<sup>43</sup> and thus remain viable throughout the culture time (Supplementary Figure S6).  
121 The clusters can be easily isolated and used for many practical purposes after the first week in  
122 culture.

123 *Evolution of nanoparticle-relevant cellular function accompanying cluster growth:* While  
124 there are many changes in cell morphology, ultra-structure, function and phenotype occurring

125 during cluster formation, it is not always clear to what degree they drive, or are a consequence  
126 of, multi-cell assembly. A broad proteomics screening comparing A549 clusters with the same  
127 cells grown as monolayer revealed major changes in the phenotype of the clusters. There is a  
128 shift toward a quiescent, secretory phenotype after the first week of culture (Supplementary  
129 Figures S7, S8, S9). Moreover, an increase in ROS defence coupled with increased  
130 mitochondrial activity and fatty acid metabolism suggests that a deep metabolic alteration,  
131 consisting of a shift toward a more ROS resistant phenotype, is occurring within the clusters in  
132 suspension.<sup>44,45</sup>

133 Cell-cell adhesion is fundamental for the stability of biological tissues, providing structural  
134 rigidity and other functional cues.<sup>46</sup> Compared to monolayer cells where the main cell  
135 interactions occur with the culture substratum, the clusters form strong cell-cell interactions  
136 immediately upon contact.<sup>47</sup> E-cadherin mRNA expression is upregulated in cells organised in  
137 clusters in the suspension media compared to monolayer grown cells, and the protein is more  
138 strongly presented at the cell surface and interface, consistent with cell-cell adhesion complex  
139 formation (Figure 2a-c and Supplementary Figure S10).

140 With the formation of clusters, an increase in cell secretory events was observed. There is a  
141 significant increase of mucin 5AC and IgG Fc binding protein mRNA expression in the cell  
142 clusters compared to monolayer, and wheat germ agglutinin (WGA) staining revealed a  
143 thickening and rearrangement of surface carbohydrate residues containing sialic acid and N-  
144 acetylglucosamine residues, consistent with increased respiratory mucus secretion<sup>48</sup> (Figure  
145 2d-g, and Supplementary Figure S11). TEM micrographs of clusters confirm that there are  
146 numerous secretory granules and vesicles within the cells after the first week of culture, with  
147 secretion of different materials (Figure 2h,i and Supplementary Figure S12). Additionally,  
148 some lysosomal activities seem to be differently regulated in the clusters, with increased  
149 expression of cathepsins and other important transcription factors, which could be related to

150 extracellular matrix remodelling (Supplementary Figure S13). Taken together, these results  
151 indicate that the A549 cell clusters grown in this way possess characteristics that more closely  
152 represent their native *in vivo* phenotype, compared to the same cells cultured in monolayer.

153 *Nanoparticle uptake, dilution, and trafficking in dividing and quiescent cell states:*

154 Traditionally, understanding the uptake and trafficking of nanoparticles in monolayer cells is  
155 complicated by the fact that upon division, cells split their intracellular contents between  
156 daughter cells, thereby diluting the nanoparticle load. Therefore, the establishment of a  
157 quiescent state in the cells organised as clusters is critical for the long-term assessment of  
158 nanoparticle interactions. A time-resolved cell cycle analysis of the clusters determined that all  
159 but the G0/G1 phases are depopulated during the first week (Figure 3a, b and Supplementary  
160 Figures S14, 15). After two weeks there are no cells in the S phase, while cell viability remains  
161 largely unaffected. Furthermore, p27<sup>kip1</sup> (a G1 cyclin complex inhibitor critical in the  
162 maintenance of quiescence<sup>49</sup>) mRNA expression is increased (Figure 3c). Consistent with this  
163 finding, Ki67 antigen (a proliferative cell marker) mRNA and protein expression is almost  
164 completely downregulated in matured clusters (Figure 3d, e, f, and Supplementary Figure S16).  
165 Together, these results suggest that the cells have exited the cell cycle and entered the quiescent  
166 (G0) phase. When cells are recovered by disassembly of the clusters and reconstituted into  
167 monolayer, they rapidly restore normal cell cycling, even after up to 3 weeks of cluster culture  
168 (Supplementary Figures S17, 18). We therefore believe that the cell clusters have established  
169 a quiescent state, which (given the intrinsic limitation of using rapidly dividing cells) is more  
170 useful for application in long-term nanoparticle studies.

171 For the cluster model presented here, cells can be exposed to particles either prior to or after  
172 formation of clusters, and the outcomes studied over many weeks (during which the cells are  
173 in their quiescent state). We present results for these exposure scenarios using polystyrene  
174 carboxylate-modified nanoparticles (PS-COOH NPs), conventionally considered non-



175 degradable and non-toxic. For the pre-cluster formation exposure method (Figure 4a), cells in  
176 monolayer were exposed to particles for 4 hours (0.1 mg/mL), then seeded in the suspension  
177 media to form clusters. Within the first days of cluster culture, the nanoparticle fluorescence  
178 loss is reduced, and after several days there is little further decrease. Indeed, for some weeks  
179 thereafter there is no significant change in the quantity of nanoparticles in cells in clusters nor  
180 any evident cell cycling, while the dividing monolayer cells have lost their nanoparticle  
181 population due to dilution (Figure 4b, c, d and Supplementary Figures 19). Confocal  
182 microscopy imaging suggests that most particles remain localised within lysosomes during  
183 those extended periods (Figure 4e and Supplementary Figure 20).

184 Significantly, this model allows for another exposure scenario, in which living quiescent  
185 suspended cell clusters can be treated directly with nanoparticles (Figure 4f). Clusters (grown  
186 for 1 week) were treated in the suspension environment with 0.02 and 0.1 mg/mL PS-COOH  
187 NPs for 4 hours, and a higher uptake was observed for both particle concentrations, in  
188 comparison with monolayer cells (Figure 4g, h, i and Supplementary Figures S21, 22). While  
189 there is still much to be learned about nanoparticle uptake and trafficking in these clusters, one  
190 key observation is that most cells in the cluster are exposed to particles, although at different  
191 levels, seemingly irrespective of their location (Figure 4 j, k, l, m, and Supplementary Figures  
192 S22, 23). Immediately after nanoparticle treatment, some particles can be seen on the surface  
193 of the cells, especially at the mucus interface (Figure 4j, k); however, 24 hours after treatment,  
194 particles are no longer observed on the surface of the clusters (Figure 4l, m). The fact that many  
195 particles are present even in cells that seem to have their external surface completely covered  
196 with mucus suggests that nanoparticles can reach the cell membrane and be internalised, even  
197 in the presence of thick mucus layers. Also, as most cells are already in their quiescent state  
198 when treated, there is little dilution of nanoparticles due to cell division, even after many weeks  
199 (Supplementary Figure S24). The minimal loss of particles from the cell clusters is an expected,

200 but significant, confirmation that much of the apparent dilution of intracellularly accumulated  
201 particles observed in recent years is indeed directly related to cell division.<sup>30</sup> These results also  
202 give us a first opportunity to meaningfully investigate the long-term consequences of  
203 intracellular nanoparticle accumulation.

204 *Modelling long-term nanoparticle exposure and degradation scenarios:* While it is not our  
205 intention here to report on exhaustive studies of long-term nanoparticle exposure, it is clear  
206 that the quiescent cluster model will allow a detailed mechanistic insight into the evolution of  
207 nanoscale materials inside living organisms. Using the exposure system described above, we  
208 illustrate the potential for valuable outcomes using examples of different types of silica  
209 nanoparticles, a material of significant practical interest. While silica has long been considered  
210 biodegradable in biological milieu, it is less well understood that this question is a matter of  
211 the material structure (dictated by the synthesis processes), as well as the details of its specific  
212 cellular localisation. We illustrate this using two different forms of silica: SiO<sub>2</sub> – an amorphous  
213 silica nanoparticle, and SiO<sub>2</sub>@SiO<sub>2</sub> – an amorphous silica nanoparticle coated with an  
214 additional, more dense layer of silica (Supplementary Figure S25).

215 Both formulations of SiO<sub>2</sub> particles show extensive degradation in biological cell culture media  
216 (cMEM), while there is little or no degradation in artificial lysosomal fluid (ALF) (Figure 5a).  
217 Accumulation in the cell lysosomes in quiescent clusters leads to slow degradation over many  
218 weeks (Figure 5b and Supplementary Figure S26, 27). The SiO<sub>2</sub> particle shows a higher degree  
219 of degradation within the lysosomes, as changes in the surface of the particle are observed,  
220 together with a decrease in particle size. Indeed, by 4 weeks in culture, some of the particles  
221 are significantly degraded with a distinct architecture no longer visible. In contrast, the  
222 SiO<sub>2</sub>@SiO<sub>2</sub> particles remain stable in the lysosomes for longer, with minimal changes in shape  
223 and size by the end of the 4 week culture period (although some etching of the surface can be  
224 observed). In no case do we observe any significant biological impacts on the cultures, even

225 when the silica slowly degrades, and currently we believe that most (amorphous) silica will  
226 degrade over quite long periods, dependent on the specific nature of the material.

227 The contrast with PS-COOH NPs is striking. It appears that these cultures can be run almost  
228 indefinitely, but for our observation time, the particles appear to remain internalised, and persist  
229 unaffected. Furthermore, there is no evident biological impact on the cells during these longer  
230 times; this could suggest that polymer nanoparticle accumulation is almost indefinite, and that  
231 any biological impacts would be very subtle and require detailed biological analysis, possibly  
232 best accomplished in cultures of this type.

233

## 234 **Conclusions**

235 To date, most studies of long-term nanoparticle effects rely on *in vivo* animal models, which  
236 are costly and significantly different to human physiology. For materials that exhibit no  
237 chemical toxicity, long-term accumulation with few observable biological outcomes leads  
238 conventional toxicological studies to a ‘dead end’ in which, while there are no observable  
239 effects, the investigative tools are absent to explore novel concepts and fully determine the  
240 final outcomes.

241 In this work we have described a long-term 3D cell cluster culture platform produced by control  
242 of the kinetics of cellular collision, division, and phenotypic evolution. When appropriate  
243 cluster formation programs are chosen, dividing cells reach a quiescent state, coupled with the  
244 establishment of an *in vivo*-like phenotype for long periods (potentially many months). These  
245 characteristics allow for longer term observations of nanoparticle cell interactions in a more  
246 relevant environment, while preventing some of the drawbacks observed in standard monolayer  
247 culture and other *in vitro* 3D culture models. Clusters formed with this technique are  
248 reproducible, stable and viable for many weeks, and may be subjected to all the advanced tools  
249 of modern molecular and cell biology. In addition, the cells comprising the clusters are

250 accessible to nanoparticles, allowing for conventional uptake studies in which all the cells  
251 accumulate and retain particles in much the same way as we believe tissue does.  
252 The need for such tools is illustrated using two different formulations of SiO<sub>2</sub> nanoparticles  
253 that degrade at different rates over several weeks depending on their synthesis method.  
254 Significantly, (hydrocarbon based) polymeric nanoparticles are found to undergo no apparent  
255 degradation over long time periods, nor do they have obvious biological impacts during this  
256 time. The availability of such cultures would now allow the whole range of modern biology to  
257 be deployed in the question of whether there could be as yet undiscovered subtle effects of  
258 nanomaterial accumulation over such very long periods of time. It is likely that question will  
259 attract considerable interest in the near future.

260

## 261 **Materials and methods**

### 262 **Cell culture**

263 A549 non-small lung carcinoma (ATCC® CCL-185™), HepG2 (ATCC® HB-8065™) and  
264 HEK-293T (ATCC® CRL-11268™) cell lines were purchased from ATCC, and cultured in  
265 MEM (Life Technologies) supplemented with 10% FBS (Life technologies) and 1%  
266 penicillin/streptomycin (referred to hereafter as cMEM). Cells were grown at 37°C in a  
267 humidified atmosphere of 5% CO<sub>2</sub> and sub-cultured at 70-80% confluence using trypsin  
268 (0.25% in EDTA). Cells were screened monthly for mycoplasma contaminations using the  
269 MycoAlert™ Mycoplasma Detection Kit, and all cultures were free of contamination for the  
270 duration of experiments reported.

271

### 272 **Nanoparticles**

273 FluoSpheres™ Carboxylate-Modified yellow-green fluorescent (505/515) polystyrene  
274 nanoparticles (PS-COOH NPs; d: 100 nm) were used throughout the study (F8803; Thermo  
275 Fisher Scientific). Characterization of the particles in PBS and cMEM was performed by  
276 dynamic light scattering (DLS) measurement (Supp. Figure S28 and Table S4). Dye release  
277 from the particles under different conditions was tested by SDS-PAGE (figure S30).

278 Silica (SiO<sub>2</sub>) nanoparticles were prepared as described previously.<sup>50,51</sup> Briefly, a fluorescein  
279 isothiocyanate - silane conjugate (FITC-APTMS) solution was prepared as follows: FITC (4  
280 mg) was dissolved in 2 ml of anhydrous ethanol, and 20 µL of (3-Aminopropyl)-  
281 trimethoxysilane (APTMS) was added. The mixture was incubated at room temperature while  
282 shaking for 4 hours, protected from light.<sup>52</sup>

283 *Preparation of the SiO<sub>2</sub> seeds:*

284 A solution composed of 21.6 mL ethanol and 0.24 ml tetraethyl orthosilicate (TEOS) was  
285 added quickly to a solution composed of 21.6 ml ethanol, 1.18 ml of NH<sub>4</sub>OH solution (28-30  
286 % w/w) and 114 µL of water. The mixture was left to react at room temperature for 2 hours.

287 *Growing of the SiO<sub>2</sub> NP to 100 nm:*

288 A solution composed of 57.8 mL ethanol, 19.6 mL water, 1.12 ml NH<sub>4</sub>OH (28-30 % w/w), and  
289 7 mL of the SiO<sub>2</sub> seed dispersion was prepared. Then 50 μL of FITC-APTMS solution and 100  
290 μL of TEOS were added. After 30 mins, another 50 μL of the dye conjugate solution and 100  
291 μL of TEOS was added. Then every 30 mins thereafter, 100 μL of the dye conjugate solution  
292 and 200 μL of TEOS was added until the particles reached a diameter of approximately 100  
293 nm. Three hours after the last addition of TEOS, the NH<sub>4</sub>OH was removed by evaporation  
294 under reduced pressure and the dispersion was centrifuged at 14,000 g during 10 min. The SiO<sub>2</sub>  
295 particles were washed 3 times with water by centrifugation.

296 *Addition of the protective SiO<sub>2</sub> layer:*

297 To make the SiO<sub>2</sub>@SiO<sub>2</sub> particles, the SiO<sub>2</sub> nanoparticles were dispersed at 20 g/L and split  
298 into 2 mL centrifuge tubes (1.5 ml/tube) then 7 μL of TEOS was added to each tube and the  
299 dispersion was heated while stirring at 90°C for 1 hour. Another 7 μL was added and the  
300 particles were incubated again at 90°C for 3 hours. The particles were then washed with water  
301 3 times by centrifugation.

302 Size distribution of the SiO<sub>2</sub> nanoparticles was determined by DLS measurement after  
303 dispersion in water together with the zeta potential using a Zetasizer ZS series (Supp. Table  
304 S3), differential centrifugal sedimentation (DCS), considering a colloidal SiO<sub>2</sub> density of  
305 2 g/cm<sup>3</sup> in a sucrose gradient (8-24% w/w in water), and transmission electron microscopy  
306 (TEM) (Supp. Figure S25, Supp. Table S2).

307

### 308 **Cell seeding and nanoparticle exposure**

309 A549 cells (2.5 x 10<sup>6</sup>) were seeded in 75 cm<sup>2</sup> flasks (in cMEM) and left to adhere for 24 hours.  
310 Prior to cell exposure, PS-COOH NPs were incubated at a final concentration of 0.1 mg/mL in  
311 cMEM at 37°C for 1 hour (to form the protein corona). Cells were exposed to this nanoparticle  
312 suspension for 4 hours at 37°C in a humidified atmosphere of 5% CO<sub>2</sub>, while control cells  
313 received cMEM without nanoparticles. The suspension was then removed and the cells were  
314 washed twice with cMEM and twice with PBS. After this washing step, cells were harvested  
315 by trypsinisation and used for the following experiments.

316

317

### 318 **Cluster formation**

319 Suspension media (SM) was prepared by diluting Happy Cell additive (Vale Life Sciences)  
320 from the stock solution of 4X to 1.7X with MEM supplemented with 1%  
321 penicillin/streptomycin, and FBS was added to the solution to reach a final concentration of  
322 10%. A549 cells were harvested from monolayer culture and resuspended in SM to a  
323 concentration of 10<sup>5</sup> cells/ml. 24 well plates were precoated with 400 μl of 1% agarose (Merck-  
324 Sigma) in MEM as described previously,<sup>53</sup> and then 700 μl of ASM was added on top. 1 ml of  
325 SM containing the cells was then gently pipetted on top of this layer (this helps to avoid cell  
326 sedimentation at the bottom of the well), resulting in a final cell number of 10<sup>5</sup> cells/well.  
327 Cluster formation was monitored during the following days by light microscopy, and a portion  
328 of media was exchanged every other day.

329

### 330 **Cluster harvesting**

331 Cells in SM were harvested directly from the well and collected in falcon tubes. Inactivation  
332 solution (Vale Life Sciences) was added to the cluster suspension to a final concentration of  
333 60 μg/ml, followed by 30 minutes incubation at 37°C in a humidified atmosphere of 5% CO<sub>2</sub>.  
334 After incubation, 7 ml of cMEM was added to the falcon tube to dilute the SM, and the clusters  
335 were collected by centrifugation at 1,500 RPM for 3 minutes at room temperature. Supernatant

336 was removed, and the cells were resuspended in an appropriate buffer dependant on subsequent  
337 processing.

338

### 339 **Cluster disassembly and reseeding as monolayer culture**

340 Clusters were harvested as described above every week and treated with Accutase® solution  
341 (Merck-Sigma) for 20 minutes at 37°C in a humidified atmosphere of 5% CO<sub>2</sub>. The solution  
342 was pipetted thoroughly every 10 minutes to help the separation of the clusters into single cells.  
343 Cells were then resuspended in fresh cMEM and seeded in 6 well plates, where they were  
344 harvested for analysis after 24 and 72 hours using trypsin.

345

### 346 **Nanoparticle exposure to cell clusters**

347 Prior to cell cluster exposure, the PS-COOH nanoparticles were incubated at a concentration  
348 of 1 mg/ml or 0.2 mg/ml in cMEM for 1 hour at 37°C to form the corona. Then 10% (volume)  
349 of the SM containing clusters was removed from each well and substituted with the  
350 nanoparticle suspension and mixed well (final concentration of the NPs in the well: 100 µg/ml  
351 or 20 µg/ml). NP dispersion was checked by differential centrifugal sedimentation (DCS, Sup.  
352 Figure S29). Cell clusters treated with cMEM with no particles were used as a control. After 4  
353 hours of incubation, cell clusters were harvested from the SM as previously described and  
354 washed twice with cMEM then twice with PBS to remove excess non-internalised particles.  
355 Clusters were then resuspended in fresh SM and cultured for extended periods (up to 2 weeks)  
356 or used immediately.

357

### 358 **Nanoparticle uptake assessment by flow cytometry**

359 To dissociate the cell clusters for analysis by flow cytometry, they were harvested from SM  
360 and washed once with PBS then disassembled using Accutase® solution (Merck-Sigma) as  
361 previously described. Cells were then resuspended in 150 µl of cold PBS and immediately  
362 analysed with an Accuri C6 (Becton Dickinson) with the following settings: flow rate 14  
363 µl/min, factory laser and filter settings. To assess the cell uptake of nanoparticle, the fluorescent  
364 signal of the internalised NPs was measured (excitation/emission 488/530 nm) for ≥10000  
365 events collected in the population gated for single cells (gating strategy is presented in  
366 Supplementary Figure S14).

367

### 368 **Cell cycle analysis**

369 The cell cycle of cells in monolayer or in clusters was assessed throughout the culture period  
370 using DNA and 5-ethynyl-2'-deoxyuridine (EdU) staining. Briefly, cells from monolayer  
371 culture or suspension were treated for 1 hour with EdU, clusters were disassembled and then  
372 fixed in 70% ethanol overnight at -20°C. Cells were stained using the Alexa 488 Click-It EdU  
373 flow cytometry kit (Thermo Fisher) following manufacturer instructions. Before analysis, cells  
374 were resuspended in 1 µM Vybrant Dycycle ruby stain (Thermo Fisher) in PBS and incubated  
375 at 37°C for 30 minutes, then resuspended in PBS and analysed with an Accuri C6 (Becton  
376 Dickinson) with the following settings: flow rate 14 µl/min, factory laser and filter settings.  
377 For each sample, ≥10,000 events in the population gated for single cells were collected (gating  
378 strategy is presented in Supplementary Figure 14).

379

### 380 **mRNA expression analysis**

381 Cells were harvested from the SM or monolayer and washed once with PBS. Total RNA was  
382 extracted from cells using the Invitrap® Spin total RNA minikit (Invitek molecular) then  
383 quantified using a Nanodrop 2000 (Thermo Fisher). RNA quality was checked using a

384 Bioanalyser (Agilent), with all samples having an RIN number of at least 8. cDNA was then  
385 obtained by reverse transcription using the High-Capacity cDNA Reverse Transcription Kit  
386 (Applied Biosystems) following manufacturer instructions. For qPCR analysis, SYBR<sup>TM</sup>  
387 Green PCR master mix (Thermo Fisher) was used together with the primers for the following  
388 genes of interest: Ki67, p27, E-CAD, MUC5AC, IgGFc, CTSS, CTSL1, CTSS, CTSZ,  
389 TFEB; GAPDH was used as the housekeeping gene (Supplementary Table S5). Comparative  
390  $\Delta$ Ct method ( $\Delta\Delta$ Ct) was used to calculate fold change in mRNA expression of targets.

391

### 392 **MTS assay**

393 For monolayer cells the MTS assay (Promega) was performed following manufacturer  
394 instructions, using 1 minute incubation with 0.1% Triton X-100 (Merck-Sigma) for the positive  
395 control for cytotoxicity. For cell clusters, a modification of the protocol was necessary. Briefly,  
396 clusters were harvested from the SM as previously described, then resuspended in PBS and  
397 divided into two equal volume samples. For both untreated and NP treated samples, one of the  
398 two parts was treated with Accutase<sup>®</sup> as described and then resuspended in PBS. For the  
399 untreated sample, this part was used to count the number of cells. Based on the number  
400 obtained, a volume of the untouched clusters was taken to make a solution with  $5 \times 10^4$  cells in  
401 1.1 ml of MTS in cMEM. Same volume was used also for the NP treated sample, assuming  
402 that same number of cells was seeded in the beginning of the experiment. Then, 110  $\mu$ l of MTS  
403 solution (containing around  $5 \times 10^3$  cells in clusters for the untreated sample) were seeded in a  
404 96 well plate in 3 technical replicates and incubated at 37°C and 5% CO<sub>2</sub> for one hour. Results  
405 were then obtained by measuring absorbance at 490 nm using a plate reader (Varioskan Flash,  
406 ThermoFisher).

407

### 408 **Live/Dead staining**

409 Live-dead staining was performed on disassembled clusters. Briefly, 3  $\mu$ M DRAQ-7 dye  
410 (BioStatus) was used to stain the cells was used to stain the cells suspended in PBS and  
411 incubated on ice for 5 minutes, and the percentage of live and dead cells was recorded using  
412 an accuri C6 (Becton Dickinson) with factory laser and filter settings. > 10,000 events were  
413 recorded per sample (gating strategy is presented in Supplementary Figure S14).

414

415

### 416 **Mass spectrometry analysis**

417 Monolayer cells were washed 3 times with ice cold PBS and then harvested using a scraper.  
418 Clusters were harvested as described and washed 3 times with ice cold PBS. Following  
419 centrifugation, cell pellets were resuspended in 8 M urea lysis buffer (8 M urea, 50 mM  
420 NH<sub>4</sub>HCO<sub>3</sub>, and 1 mM EDTA, pH 8; reagents from Merck-Sigma) containing protease  
421 inhibitors (cOmplete mini, Roche). Short sonication was used to break the cells and to fragment  
422 the nuclear DNA, then the mixture was centrifuged at 20,000 x g for 15 minutes to pellet DNA  
423 and cell debris. The supernatant total protein was collected and quantified by BCA assay  
424 (Thermo Fisher) and 40  $\mu$ g was for preparation for mass spectrometry analysis. Briefly, the  
425 total lysate was first reduced using DTT (10 mM), and alkylated by iodoacetamide (40 mM),  
426 and then digested over night at room temperature using trypsin (enzyme to substrate ratio 1:50;  
427 Thermo Fisher). Resulting peptides were purified using Pierce<sup>TM</sup> C18 high capacity tips  
428 (Thermo Fisher), and then dried and resuspended in 0.1% formic acid (Merck-Sigma). Analysis  
429 was performed on technical triplicates by electrospray liquid chromatography mass  
430 spectrometry (LC-MS/MS) using an HPLC (Thermo Fisher) interfaced with an LTQ Orbitrap

431 (Thermo Fisher). MaxQuant and Perseus Software (Computational Systems Biochemistry,  
432 Max Planck institute, Martinsried) were used to analyse the data.

433

#### 434 **Cluster formation timelapse imaging**

435 Cell clusters in SM were imaged directly in their plate using a Zeiss Axiovert 200M inverted  
436 microscope with brightfield illumination and a 10x air objective. The cells were maintained at  
437 37°C and 5% CO<sub>2</sub> for 24 hour timelapse (2 hour capture increment) and 48, 72, 96 and 120  
438 hours timelapse (3 hour capture increments), using the Zeiss software associated with the  
439 microscope. Further analysis of the images was performed using ImageJ software.

440

#### 441 **Spinning disc confocal Imaging**

442 Cell clusters were imaged using 96-well glass bottom plates (Greiner Bio-one) on a Nikon  
443 eclipse TI spinning disc confocal microscope. Clusters were fixed and permeabilised prior to  
444 immunostaining with 4% paraformaldehyde and 0.1 Triton-X 100 (permeabilisation was not  
445 needed for anti E-cadherin antibody). Antibodies used: Ki67 (Abcam ab92742), E-Cadherin  
446 (Abcam ab40772) and LAMP-1 (Abcam ab24170). As secondary antibody, an Alexa 546 was  
447 used in combination with every primary antibody (Thermo Fisher A11030 and Thermo Fisher  
448 A11035). Images were analysed with Imaris imaging software (Bitplane) and ImageJ. For  
449 wheat germ agglutinin (WGA) staining, the cell clusters were incubated with WGA 594 (5  
450 µg/ml) for 15 minutes at 37°C in a humidified atmosphere of 5% CO<sub>2</sub> and then washed with  
451 PBS and fixed with 4% paraformaldehyde. DAPI (2 µg/ml) was used to counterstain the nuclei  
452 of fixed cells prior to imaging. The Imaris imaging software was also used to render in 3D the  
453 images in figure 1f and S4.

454

#### 455 **High content screening**

456 For cluster diameter assessment, cells were treated with WGA 594 and DAPI as previously  
457 described, and then imaged in 96 well glass bottom plates (Greiner Bio-one) using an Opera  
458 Phenix<sup>TM</sup> high content spinning disc microscope (Perkin Elmer). Long axis length distribution  
459 was assessed using the algorithm provided by the proprietary software (Harmony High-Content  
460 Imaging and Analysis software, Perkin Elmer). > 1,000 clusters were analysed for each  
461 timepoint.

462

#### 463 **Transmission electron microscopy**

464 Cell clusters were washed with PBS and immediately fixed with 2.5% glutaraldehyde in 0.1 M  
465 Sorensen phosphate buffer, rinsed with Sorensen phosphate buffer, and then post-fixed for 1  
466 hour in 1% osmium tetroxide in deionised water. Cells were dehydrated in a graded ethanol  
467 series (from 70% to 100%), followed by Acetone rinse. Samples were then immersed in an  
468 Acetone/Epon (1:1 vol/vol) mixture for 1h before being transferred to pure Epon and  
469 embedded at 37°C for 2h. The final polymerization was carried out at 60°C for 24h. Ultrathin  
470 sections of 80 nm, obtained with a diamond knife using an ultra-microtome Leica U6, were  
471 supported on copper grids. Sections were stained with uranyl acetate and lead citrate before  
472 being examined with an FEI TECNAI transmission electron microscope.

473

#### 474 **Statistical analysis**

475 All data are shown as mean ± SD as described in the figure captions.  $p < 0.05$  was considered  
476 significant. The experiments were performed at least 3 times independently (with exception of  
477 cell cycle analysis by flow cytometry and SiO<sub>2</sub> NPs degradation assessment, with 2  
478 independent replicates, cluster size distribution with one independent replicate per operator, 2



479 in total (see supp. Figures S31, 32 for independently replicated data from other operators). The  
480 number of independent replicates (N) performed for each experiment is indicated in each figure  
481 caption. Statistical analyses were performed using Prism 6.01 (GraphPad software). Student t-  
482 test and one-way ANOVA, the first two-sided with Welch correction and the latter with Turkey  
483 correction for multiple comparisons, were used as described in the figure captions. Statistical  
484 differences are defined as \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ .

485

486 **Conflict of interest:** Authors declare no conflict of interest.

487

488 **Acknowledgments:** The authors acknowledge Ms J Li, Ms W Zhang, and Mr X Yang for the  
489 independent replications of some of the experiments. F.M. acknowledges the support of the  
490 Irish Research Council Postgraduate fellowship (GOIPG/2015/2530). A.A. acknowledges the  
491 Princess Nourah Bint Abdulrahman University Project Ref: IR10177, ID: 1056571209,  
492 M.M.C. acknowledges the support of the Irish Research Council Enterprise Partnership  
493 Scheme (Postdoctoral) 2019 - EPSPD/2019/232. The authors acknowledge Dr. A. Blanco and  
494 Dr. D. Scholtz from the Conway Institute of Biomolecular and Biomedical research centre flow  
495 cytometry and imaging core facilities in University College Dublin for their assistance, and Dr.  
496 A. Davies from Vale Lifesciences for the support.

497

498 **Supporting Information:** All supporting information is available free of charge via the  
499 Internet at <http://pubs.acs.org>.

500

501 **Author contributions:** F.M., M.M.C., and K.D. designed the experiments. F.M., A.A. and  
502 V.A.G. performed the experiments and data analysis. L.A. synthesised and characterised the  
503 two formulations of silica NP used in this study. F.M., Y.Y., M.M.C. and K.D. wrote and  
504 revised the manuscript.

505

506 **Data availability:** All relevant data during the study are available from the corresponding  
507 authors upon request.

508

- 509 1. Albanese, A., Tang, P. S. & Chan, W. C. W. The Effect of Nanoparticle Size, Shape,  
510 and Surface Chemistry on Biological Systems. *Annu. Rev. Biomed. Eng.* **14**, 1–16  
511 (2012).
- 512 2. Blanco, E., Shen, H. & Ferrari, M. Principles of Nanoparticle Design for Overcoming  
513 Biological Barriers to Drug Delivery. *Nat. Biotechnol.* **33**, 941–951 (2015).
- 514 3. Pelaz, B. *et al.* Diverse Applications of Nanomedicine. *ACS Nano* **11**, 2313–2381  
515 (2017).
- 516 4. Gong, N. *et al.* Carbon-Dot-Supported Atomically Dispersed Gold as a Mitochondrial  
517 Oxidative Stress Amplifier for Cancer Treatment. *Nat. Nanotechnol.* **14**, 379–387  
518 (2019).
- 519 5. Cedervall, T. *et al.* Understanding the Nanoparticle-Protein Corona Using Methods to  
520 Quantify Exchange Rates and Affinities of Proteins for Nanoparticles. *Proc. Natl. Acad.*  
521 *Sci.* **104**, 2050–2055 (2007).
- 522 6. Monopoli, M. P., Åberg, C., Salvati, A. & Dawson, K. A. Biomolecular Coronas Provide  
523 the Biological Identity of Nanosized Materials. *Nat. Nanotechnol.* **7**, 779–786 (2012).
- 524 7. Tenzer, S. *et al.* Rapid Formation of Plasma Protein Corona Critically Affects  
525 Nanoparticle Pathophysiology. *Nat. Nanotechnol.* **8**, 772–781 (2013).
- 526 8. Corbo, C. *et al.* The Impact of Nanoparticle Protein Corona on Cytotoxicity,  
527 Immunotoxicity and Target Drug Delivery. *Nanomedicine* **11**, 81–100 (2016).
- 528 9. Saha, K. *et al.* Regulation of Macrophage Recognition through the Interplay of  
529 Nanoparticle Surface Functionality and Protein Corona. *ACS Nano* **10**, 4421–4430  
530 (2016).
- 531 10. Tsoi, K. M. *et al.* Mechanism of Hard-Nanomaterial Clearance by The Liver. *Nat.*  
532 *Mater.* **15**, 1212–1221 (2016).
- 533 11. Lo Giudice, M. C., Herda, L. M., Polo, E. & Dawson, K. A. In Situ Characterization Of

- 534 Nanoparticle Biomolecular Interactions in Complex Biological Media by Flow  
535 Cytometry. *Nat. Commun.* **7**, 1–10 (2016).
- 536 12. Bekdemir, A. & Stellacci, F. A Centrifugation-Based Physicochemical Characterization  
537 Method for the Interaction Between Proteins and Nanoparticles. *Nat. Commun.* **7**, 1–8  
538 (2016).
- 539 13. Shapero, K. *et al.* Time and Space Resolved Uptake Study of Silica Nanoparticles by  
540 Human Cells. *Mol. Biosyst.* **7**, 371–378 (2011).
- 541 14. Saha, K. *et al.* Surface Functionality of Nanoparticles Determines Cellular Uptake  
542 Mechanisms in Mammalian cells. *Small* **9**, 300–305 (2013).
- 543 15. Liu, M. *et al.* Real-Time Visualization of Clustering and Intracellular Transport of Gold  
544 Nanoparticles by Correlative Imaging. *Nat. Commun.* **8**, 1–10 (2017).
- 545 16. Khlebtsov, N. & Dykman, L. Biodistribution and Toxicity of Engineered Gold  
546 Nanoparticles: a Review of In Vitro and In Vivo Studies. *Chem. Soc. Rev.* **40**, 1647–  
547 1671 (2011).
- 548 17. Almeida, J. P. M., Figueroa, E. R. & Drezek, R. A. Gold Nanoparticle Mediated Cancer  
549 Immunotherapy. *Nanomedicine Nanotechnology, Biol. Med.* **10**, 503–514 (2014).
- 550 18. Loos, C. *et al.* Functionalized Polystyrene Nanoparticles as a Platform for Studying Bio-  
551 Nano Interactions. *Beilstein J. Nanotechnol.* **5**, 2403–2412 (2014).
- 552 19. Talamini, L. *et al.* Influence of Size and Shape on the Anatomical Distribution of  
553 Endotoxin-Free Gold Nanoparticles. *ACS Nano* **11**, 5519–5529 (2017).
- 554 20. Soenen, S. J. H. *et al.* Colloidal Gold Nanoparticles Induce Changes in Cellular and  
555 Subcellular Morphology. *ACS Nano* **11**, 7807–7820 (2017).
- 556 21. Sandin, P. *et al.* The Biomolecular Corona is Retained During Nanoparticle Uptake and  
557 Protects the Cells From the Damage Induced by Cationic Nanoparticles Until Degraded  
558 in the Lysosomes. *Nanomedicine Nanotechnology, Biol. Med.* **9**, 1159–1168 (2013).

- 559 22. De Matteis, V. *et al.* Negligible Particle-Specific Toxicity Mechanism of Silver  
560 Nanoparticles: the Role of Ag<sup>+</sup> Ion Release in the Cytosol. *Nanomedicine*  
561 *Nanotechnology, Biol. Med.* **11**, 731–739 (2015).
- 562 23. Arami, H., Khandhar, A., Liggitt, D. & Krishnan, K. M. In Vivo Delivery,  
563 Pharmacokinetics, Biodistribution and Toxicity of Iron Oxide Nanoparticles. *Chem.*  
564 *Soc. Rev.* **44**, 8576–8607 (2015).
- 565 24. Gao, C. *et al.* Y<sub>2</sub>O<sub>3</sub> Nanoparticles Caused Bone Tissue Damage by Breaking the  
566 Intracellular Phosphate Balance in Bone Marrow Stromal Cells. *ACS Nano* **13**, 313–323  
567 (2019).
- 568 25. Hu, W. *et al.* Protein Corona-Mediated Mitigation of Cytotoxicity of Graphene Oxide.  
569 *ACS Nano* **5**, 3693–3700 (2011).
- 570 26. Walkey, C. D. *et al.* Protein Corona Fingerprinting Predicts the Cellular Interaction of  
571 Gold And Silver Nanoparticles. *ACS Nano* **8**, 2439–2455 (2014).
- 572 27. Sabella, S. *et al.* A General Mechanism for Intracellular Toxicity of Metal-Containing  
573 Nanoparticles. *Nanoscale* **6**, 7052–7061 (2014).
- 574 28. Jiang, Y. *et al.* The Interplay of Size and Surface Functionality on the Cellular Uptake  
575 of Sub-10 nm Gold Nanoparticles. *ACS Nano* **9**, 9986–9993 (2015).
- 576 29. Corvaglia, S., Guarnieri, D. & Pompa, P. P. Boosting the Therapeutic Efficiency of  
577 Nanovectors: Exocytosis Engineering. *Nanoscale* **9**, 3757–3765 (2017).
- 578 30. Kim, J. A., Aberg, C., Salvati, A. & Dawson, K. A. Role of Cell Cycle on the Cellular  
579 Uptake and Dilution Of Nanoparticles In A Cell Population. *Nat. Nanotechnol.* **7**, 62–  
580 68 (2012).
- 581 31. Rees, P. *et al.* Statistical Analysis of Nanoparticle Dosing in a Dynamic Cellular System.  
582 *Nat. Nanotechnol.* **6**, 170–174 (2011).
- 583 32. Lee, J., Lilly, D., Doty, C., Podsiadlo, P. & Kotov, N. In Vitro Toxicity Testing of

- 584 Nanoparticles in 3D Cell Culture. *Small* **5**, 1213–1221 (2009).
- 585 33. Huang, K. *et al.* Size-Dependent Localization and Penetration of Ultrasmall Gold  
586 Nanoparticles in Cancer Cells, Multicellular Spheroids, and Tumors In Vivo. *ACS Nano*  
587 **6**, 4483–4493 (2012).
- 588 34. Huo, S. *et al.* Superior Penetration and Retention Behavior of 50 nm Gold Nanoparticles  
589 in Tumors. *Cancer Res.* **73**, 319–330 (2013).
- 590 35. Mazuel, F. *et al.* Massive Intracellular Biodegradation of Iron Oxide Nanoparticles  
591 Evidenced Magnetically at Single-Endosome and Tissue Levels. *ACS Nano* **10**, 7627–  
592 7638 (2016).
- 593 36. Eisenstein, M. Organoids: The Body Builders. *Nat. Methods* **15**, 19–22 (2018).
- 594 37. Montenegro, J.-M. *et al.* In Vivo Integrity of Polymer-Coated Gold Nanoparticles. *Nat.*  
595 *Nanotechnol.* **10**, 619–623 (2015).
- 596 38. Martinez, J. O. *et al.* Short And Long Term, In Vitro and In Vivo Correlations of Cellular  
597 and Tissue Responses to Mesoporous Silicon Nanovectors. *Small* **9**, 1722–1733 (2013).
- 598 39. Yeung, C.-Y. *et al.* In Vivo Toxicologic Study of Larger Silica Nanoparticles in Mice.  
599 *Int. J. Nanomedicine* **12**, 3421–3432 (2017).
- 600 40. Lopez-Chaves, C. *et al.* Gold Nanoparticles: Distribution, Bioaccumulation and  
601 Toxicity. In Vitro and In Vivo Studies. *Nanomedicine Nanotechnology, Biol. Med.* **14**,  
602 1–12 (2018).
- 603 41. Wyma, A. *et al.* Non-Newtonian Rheology in Suspension Cell Cultures Significantly  
604 Impacts Bioreactor Shear Stress Quantification. *Biotechnol. Bioeng.* **115**, 2101–2113  
605 (2018).
- 606 42. Davies, A. Cell Suspension Medium and Cell Suspension Medium Additive for the  
607 Three Dimensional Growth of Cells. *Int. Pat.* **144372 A1**, (2013).
- 608 43. Curcio, E. *et al.* Mass Transfer and Metabolic Reactions in Hepatocyte Spheroids


- 609 Cultured in Rotating Wall Gas-Permeable Membrane System. *Biomaterials* **28**, 5487–  
610 5497 (2007).
- 611 44. Panieri, E. & Santoro, M. M. ROS Homeostasis and Metabolism: A Dangerous Liason  
612 in Cancer Cells. *Cell Death Dis.* **7**, e2253 (2016).
- 613 45. Davison, C. A. *et al.* Antioxidant Enzymes Mediate Survival of Breast Cancer Cells  
614 Deprived of Extracellular Matrix. *Cancer Res.* **73**, 3704–3715 (2013).
- 615 46. Gloushankova, N. A., Rubtsova, S. N. & Zhitnyak, I. Y. Cadherin-Mediated Cell-Cell  
616 Interactions in Normal and Cancer Cells. *Tissue Barriers* **5**, 1–15 (2017).
- 617 47. Pampaloni, F., Reynaud, E. G. & Stelzer, E. H. K. The Third Dimension Bridges the  
618 Gap Between Cell Culture and Live Tissue. *Nat. Rev. Mol. Cell Biol.* **8**, 839–845 (2007).
- 619 48. Thornell, I. M. *et al.* Gel-Forming Mucins Form Distinct Morphologic Structures in  
620 Airways. *Proc. Natl. Acad. Sci.* **114**, 6842–6847 (2017).
- 621 49. Endl, E. *et al.* The Expression of Ki-67, MCM3, and P27 Defines Distinct Subsets of  
622 Proliferating, Resting, and Differentiated Cells. *J. Pathol.* **195**, 457–462 (2001).
- 623 50. Reinhardt, N., Adumeau, L., Lambert, O., Ravaine, S. & Mornet, S. Quaternary  
624 Ammonium Groups Exposed at the Surface of Silica Nanoparticles Suitable for DNA  
625 Complexation in the Presence of Cationic Lipids. *J. Phys. Chem. B* **119**, 6401–6411  
626 (2015).
- 627 51. Adumeau, L. *et al.* Impact of Surface Grafting Density of PEG Macromolecules on  
628 Dually Fluorescent Silica Nanoparticles Used for the In Vivo Imaging of Subcutaneous  
629 Tumors. *Biochim. Biophys. Acta - Gen. Subj.* **1861**, 1587–1596 (2017).
- 630 52. Mahon, E., Hristov, D. R. & Dawson, K. A. Stabilising Fluorescent Silica Nanoparticles  
631 Against Dissolution Effects for Biological Studies. *Chem. Commun.* **48**, 7970–7972  
632 (2012).
- 633 53. Friedrich, J., Seidel, C., Ebner, R. & Kunz-Schughart, L. A. Spheroid-Based Drug

634 Screen: Considerations and Practical Approach. *Nat. Protoc.* **4**, 309–324 (2009).

635

636






637

638 **Figure 1: Formation and evolution of the cell clusters.** a, Schematic illustration of the key  
 639 steps for cluster formation: an agar coating is first deposited to avoid cell attachment, and then

640 a layer of suspension media is added; cells are seeded on top of this layer to avoid excessive  
641 precipitation. **b**, Schematics of cluster formation and growth: when cells are suspended within  
642 the suspension media, several stages of cluster growth occur. In the first hours most cells are  
643 singlets and can move and divide more often. Some cells eventually come in contact and  
644 aggregate and so, in the second stage some clusters begin to form and become less mobile. In  
645 the third stage most clusters are fully formed, and further growth is limited. **c**, Gaussian fitting  
646 of the distribution of cell cluster diameters determined by high content analysis microscopy  
647 show that growth is more rapid in the first 5 days, and then slows thereafter. This is supported  
648 by **d**, extrapolation of the median and mean long axis length. **e**, Representative images of the  
649 clusters at different time-points showing the initial growth and then a more stationary phase.  
650 Nuclei are blue (DAPI) and plasma membrane is red (WGA547), scale bars = 50  $\mu\text{m}$ . **f**, 3D  
651 reconstruction of clusters shows they are organised as an oblate shape and not spherical (scale  
652 bars = 20  $\mu\text{m}$ ).

653



654

655

656

657


658

659

660

**Figure 2: mRNA and protein expression analysis of the clusters suggests a differentiation of the cell phenotype towards a more *in vivo*-like representation. a, Increased E-cadherin gene expression in clusters, together with confocal imaging (b and c) reveals a stronger interaction between neighboring cells in suspension, compared to those grown in monolayer. d, A significant upregulation of mucin 5AC and IgG Fc binding protein (e) expression suggests**

661 an increase of mucus secretion from cells in the clusters (N = 4 mean  $\pm$  SD; \* p < 0.05; \*\* p <  
662 0.01; \*\*\* p < 0.001, calculated using one way ANOVA). This is supported by confocal image  
663 analysis of WGA stained monolayer cells (**f**) compared to 1 week old clusters (**g**) that show  
664 layers of mucus on the latter (scale bars = 20  $\mu$ m). **h**, Representative TEM micrograph of a cell  
665 cluster after 3 weeks of culture shows very dense secretory granules in all the visible cells  
666 (circle and arrows; scale bar = 5  $\mu$ m); **i**, mucus granules can be seen on the exterior of the cells  
667 (scale bar = 0.5  $\mu$ m).  
668



670

671

672 **Figure 3: Cells cultured as clusters exit the cell cycle and are maintained in a quiescent**673 **state. a**, EdU vs dsDNA content scatter plots obtained by flow cytometry analysis show


674 changes in cell cycle phase distribution of monolayer and suspension cells after 24 hours and

675 2 weeks. **b**, The majority of cells are in the G0/1 phase after 1 week of suspension culture (N676 = 2, mean ± SD). **c**, Upregulation of p27<sup>Kip1</sup> (a cell cycle inhibitor) together with the677 downregulation of Ki67 (a proliferative cell marker) (**d**) suggests that the cells in clusters have

678 exited the cell cycle (mean ± SD, N = 4; \* p &lt; 0.05; \*\* p &lt; 0.01; \*\*\* p &lt; 0.001, calculated

679 using one way ANOVA); **e**, Immunocytochemical localisation of Ki67 shows that while the



680 protein is present in the nucleus of all cells in monolayer, in clusters (**f**) it is mostly absent  
681 (scale bars = 20  $\mu\text{m}$ ).  
682



684 **Figure 4: Evaluation of polystyrene nanoparticle accumulation in clusters.** **a**, Schematic  
685 illustration of nanoparticle treatment of cells in monolayer prior to cluster formation. **b**, The  
686 intracellular PS-COOH NP fluorescence intensity for monolayer cells decreased continually,  
687 while for the clusters, after an initial decrease of signal in first week, there was no significant  
688 reduction thereafter (N = 3, mean  $\pm$  SD). **c-d**, Confocal imaging of monolayer and cell clusters  
689 stained with WGA and DAPI 2 weeks from PS-COOH NP exposure shows that while few  
690 particles are detected in the monolayer cells, many are still present within the cells in clusters.  
691 **e**, LAMP1 immunostaining confirms nanoparticle localisation in lysosomes after 2 weeks of  
692 exposure in clusters. **f**, Schematic illustration of nanoparticle treatment of cells directly in  
693 clusters. **g**, There is a significantly higher uptake in clusters compared to monolayer (N = 3 for  
694 0.02 mg/mL, N = 4 for 0.1 mg/mL; mean  $\pm$  SD; \*\*\* p < 0.001, calculated using t-test). **h**,  
695 Confocal imaging of disassembled clusters confirms a higher nanoparticle content in cells in  
696 clusters compared to those in monolayer (**i**). **j,l**, maximum projection and (**k,m**) single Z-stack  
697 imaging of clusters treated with nanoparticles at 0h chase time (**j-k**) and 24 hours chase time  
698 (**l-m**) after treatment. Right after treatment many particles are still present on the surface of the  
699 clusters, while at 24 hours all particles seem to be internalised (all scale bars in this figure = 20  
700  $\mu$ m).

701





704 **Figure 5: TEM micrographs of SiO<sub>2</sub> and SiO<sub>2</sub>@SiO<sub>2</sub> NPs degradation in biological media**  
705 **and A549 cell clusters. a,** In cMEM both SiO<sub>2</sub> and SiO<sub>2</sub>@SiO<sub>2</sub> nanoparticles show extensive  
706 degradation over a period of 2 weeks, while in artificial lysosomal fluid (ALF) no real effect  
707 is observed. **b,** In A549 cell clusters, while SiO<sub>2</sub>@SiO<sub>2</sub> nanoparticles show only slight etching  
708 on their surfaces after 4 weeks, for non-coated SiO<sub>2</sub> nanoparticles a greater degradative effect  
709 due to lysosomal action can be observed over the culture duration (scale bars = 100 nm).  
710